Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10790876 | 0.80 | CA12 (0.63) | ADORA3ADORA2AADORA1CA12CA1 | |
| SCHEMBL10600516 | 0.79 | CA12 (0.64) | ADORA3ADORA2AADORA1CA12CA1 | |
| SCHEMBL21797929 | 0.77 | AHR (0.39) | MEN1NPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL10602632 | 0.75 | CA12 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18306420 | 0.75 | MAOA (0.71) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11622074 | 0.75 | CTRC (0.43) | ADORA3ADORA2AADORA1CA12CA1 | |
| SCHEMBL16119578 | 0.73 | MAOB (0.72) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL16119539 | 0.73 | MAOA (0.49) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL16119705 | 0.72 | LMNA (0.41) | ADORA3ADORA2AADORA1MEN1NPC1 | |
| SCHEMBL830518 | 0.71 | PGR (0.47) | ADORA3ADORA2AADORA1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | DISCOVERYBIOMED, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2970249-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | Discoverybiomed Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970248-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | Discoverybiomed Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152213-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152213-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | CFTR, SLC47A1, ABCB11 | ELANE 453/4885ADORA3 3542/4885ADORA2A 4553/4885 |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | HSP90B1, HSPD1, HSPE1 | ELANE 1499/4885ADORA3 4656/4885ADORA2A 4726/4885 |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | HSP90B1, HSPD1, HSPE1 | ELANE 1499/4885ADORA3 4656/4885ADORA2A 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.